Studies have confirmed that PROTACs can effectively induce the degradation of Brd4, which is more effective than JQ1 and other traditional Brd4 inhibitors in inhibiting tumor cell growth and promoting cell apoptosis [37, 160]. Here, BRD4 is linked to neoplasm.